197 related articles for article (PubMed ID: 33474679)
61. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
[TBL] [Abstract][Full Text] [Related]
62. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.
Lu D; Joshi A; Wang B; Olsen S; Yi JH; Krop IE; Burris HA; Girish S
Clin Pharmacokinet; 2013 Aug; 52(8):657-72. PubMed ID: 23553425
[TBL] [Abstract][Full Text] [Related]
63. The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence.
Giuliani J; Bonetti A
Breast J; 2021 Jan; 27(1):75-76. PubMed ID: 32920921
[No Abstract] [Full Text] [Related]
64. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
65. A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
Barfield RM; Kim YC; Chuprakov S; Zhang F; Bauzon M; Ogunkoya AO; Yeo D; Hickle C; Pegram MD; Rabuka D; Drake PM
Mol Cancer Ther; 2020 Sep; 19(9):1866-1874. PubMed ID: 32651200
[TBL] [Abstract][Full Text] [Related]
66. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
Jacot W; Pons E; Frenel JS; Guiu S; Levy C; Heudel PE; Bachelot T; D'Hondt V; Darlix A; Firmin N; Romieu G; Thezenas S; Dalenc F
Breast Cancer Res Treat; 2016 Jun; 157(2):307-318. PubMed ID: 27167986
[TBL] [Abstract][Full Text] [Related]
67. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
[No Abstract] [Full Text] [Related]
68. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
69. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
70. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K
Oncology; 2019; 96(6):309-317. PubMed ID: 30893699
[TBL] [Abstract][Full Text] [Related]
71. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
[TBL] [Abstract][Full Text] [Related]
72. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Le QA; Bae YH; Kang JH
Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
[TBL] [Abstract][Full Text] [Related]
73. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
[TBL] [Abstract][Full Text] [Related]
74. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
Le Joncour V; Martins A; Puhka M; Isola J; Salmikangas M; Laakkonen P; Joensuu H; Barok M
Mol Cancer Ther; 2019 Oct; 18(10):1721-1730. PubMed ID: 31292166
[TBL] [Abstract][Full Text] [Related]
75. Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.
Lyseng-Williamson KA
Drugs; 2020 Nov; 80(16):1723-1730. PubMed ID: 32996066
[TBL] [Abstract][Full Text] [Related]
76. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Krop IE; Kim SB; González-Martín A; LoRusso PM; Ferrero JM; Smitt M; Yu R; Leung AC; Wildiers H;
Lancet Oncol; 2014 Jun; 15(7):689-99. PubMed ID: 24793816
[TBL] [Abstract][Full Text] [Related]
77. [Clinical research progress of T-DM1 in breast cancer].
Li LX; Ma F
Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):92-97. PubMed ID: 33472319
[TBL] [Abstract][Full Text] [Related]
78. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA
Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926
[TBL] [Abstract][Full Text] [Related]
79. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.
Doroshow DB; LoRusso PM
Future Oncol; 2018 Mar; 14(7):589-602. PubMed ID: 29214842
[TBL] [Abstract][Full Text] [Related]
80. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
